drugset / Trial / NCT01144455

Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma

NCT01144455

Phase 2 Completed 214 enrolled ImmunoGenesis PRA Health Sciences · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether Gemcitabine versus Gemcitabine and TH-302 are effective in the treatment of subjects with first-line metastatic pancreatic adenocarcinoma.

Timeline

Start
2010-06
Primary completion
2013-09
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Evofosfamide Other / unclassified 240 mg/m2 Intravenous
Subject Evofosfamide Other / unclassified 340 mg/m2 Intravenous
Subject Gemcitabine Small molecule 1000 mg/m2 Intravenous